Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases

Ann Oncol. 2008 Sep;19(9):1634-8. doi: 10.1093/annonc/mdn182. Epub 2008 May 7.

Abstract

Background: Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well characterized.

Patients and methods: We describe a cohort of seven patients and discuss 94 additional cases from the literature for whom biological parameters were described. Cases with incomplete data were excluded.

Results: Hodgkin's disease (HD) was more common in the 18-59 age group while breast and prostate cancers were prevalent only in the >or=18-year-old patients. The time interval to develop sALL was similar among all age groups but was significantly longer for HD and neuroblastoma primary diagnoses and sALL with complex karyotype. T-cell immunophenotype was more common in the <18 age group. Complete remission was infrequent in the >or=60 age group. The overall survival was poor for all sALL regardless of age, primary diagnoses, cytogenetic subgroups, or immunophenotype. Allogeneic transplantation most probably represents the only chance of cure.

Conclusion: Better identification of prognostic factors to prevent the occurrence of sALL is indicated.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Analysis of Variance
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Biopsy, Needle
  • Cause of Death*
  • Cohort Studies
  • Combined Modality Therapy
  • Female
  • Hodgkin Disease / mortality
  • Hodgkin Disease / pathology
  • Hodgkin Disease / therapy
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid / mortality
  • Leukemia, Myeloid / pathology
  • Leukemia, Myeloid / therapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms, Second Primary / mortality*
  • Neoplasms, Second Primary / pathology
  • Neoplasms, Second Primary / therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Prognosis
  • Risk Factors
  • Sex Factors
  • Statistics, Nonparametric
  • Stem Cell Transplantation
  • Survival Analysis
  • Treatment Outcome